查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133250

白血病治療藥的全球市場:各治療類型，白血病的各類型，各分子類型 - 各地區展望，競爭策略，各市場區隔預測(～2030年)

Leukemia Therapeutics Market- By Treatment Type, By Type of Leukemia, By Molecule Type - Regional Outlook, Competitive Strategies, and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 208 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球白血病治療藥的市場規模，預計至2030年達到359億6,000萬美元，預計以11.3％的年複合成長率成長。

罹患白血病的人數增加，血液癌症篩檢領域的技術改善和突破，牽引全球白血病治療藥市場。再加上預防醫療的重要性相關人們的意識高漲，也預計牽引在預測期間內的市場。

本報告提供全球白血病治療藥市場相關調查，市場動態，市場變數及預測，各治療類型、白血病的類型、分子類型、地區分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，及課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • COVID-19對全球白血病治療藥市場的影響

第5章 市場變數及預測

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球白血病治療藥市場:各治療類型，2019年～2030年(100萬美元)

  • 化療
  • 免疫療法
  • 標靶治療
  • 其他的治療方法

第7章 全球白血病治療藥市場:白血病的各類型，2019年～2030年(100萬美元)

  • 急性淋巴性白血病
  • 急性骨髓性白血病
  • 慢性淋巴性白血病
  • 慢性骨髓性白血病
  • 其他的白血病類型

第8章 全球白血病治療藥市場:各分子類型，2019年～2030年(100萬美元)

  • 低分子化合物
  • 生技藥品

第9章 全球白血病治療藥市場:各地區，2019年～2030年(100萬美元)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • AbbVie Inc.
    • 企業概要
    • 財務預測
    • 產品概要
    • 最近的開發
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company Ltd.
  • Gilead Sciences Inc.
  • iCell Gene therapeutics
  • Merck & Company Inc.
  • Novartis AG
  • Otsuka Holdings Company Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Stemline Therapeutics Inc.
  • Takeda Pharmaceutical Company Ltd.
簡介目錄
Product Code: HLCA2210

According to SPER Market Research, the Global Leukemia Therapeutics Market is estimated to reach USD 35.96 billion by 2030 with a CAGR of 11.3%.

Leukemia is a type of blood cancer that affects the bone marrow and lymphatic system. It affects leucocytes, or white blood cells, as the name implies. The DNA of leucocytes is broken in this type of cancer, causing them to proliferate and divide uncontrollably. These cells continue to develop and accumulate, preventing healthy white blood cells from forming and functioning.

Leukemia can be acute or chronic, affecting both red blood cells and platelets. Fever, night sweats, weight loss, an enlarged liver, frequent infections, and swollen lymph nodes are all common symptoms of leukemia. Some of the numerous kinds of leukemia are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. Acute myeloid leukemia, also known as acute myelogenous leukemia, is most common in adults.

Because of the increased number of people suffering from leukemia, technical improvements and breakthroughs in the field of blood cancer testing are driving the Global Leukemia Therapeutics Market. Furthermore, rising public awareness about the importance of preventive healthcare is likely to drive the market throughout the forecast period. Government initiatives and policies encouraging cancer awareness are expected to drive market expansion until 2026.

Impact of COVID-19 on the Global Leukemia Therapeutics Market

The risk of infection is low in treating Leukemia during COVID-19 times. Although the mortality rate maybe be higher in patients with leukemia and COVID-19. Furthermore, according to the study "Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicentre Study During the COVID-19 Outbreak," published in Cancer Discovery in June 2021, the risk of severe COVID-19 infection was found to be higher, at around 57 percent, among patients with blood cancers.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered By Treatment Type, By Type of Leukemia, By Molecule Type

Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company Ltd., Gilead Sciences Inc. ICell Gene therapeutics, Merck & Company Inc., Novartis AG, Otsuka Holdings Company Ltd., Pfizer Inc., Roche HoldingAG, Stemline Therapeutics Inc., Takeda Pharmaceutical Company Ltd.

Global Leukemia Therapeutics Market, By Treatment Type:

Based on the Treatment Type, Global Leukemia Therapeutics Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy, and Other Treatments

Global Leukemia Therapeutics Market, By Type of Leukemia:

Based on the Type of Leukemia, Global Leukemia Therapeutics Market is segmented as; Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Other Type of Leukemias.

Global Leukemia Therapeutics Market, By Molecule Type:

Based on the Molecule Type, Global Leukemia Therapeutics Market is segmented as; Small Molecules and Biologics.

Global Leukemia Therapeutics Market, By Region:

The Asia Pacific emerged as the leading region in the Global Leukemia Therapeutics Market with the maximum market share in 2021.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data Triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges Analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts on the Global Leukemia Therapeutics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Leukemia Therapeutics Market, By Treatment Type, 2019-2030 (USD Million)

  • 6.1. Chemotherapy
  • 6.2. Immunotherapy
  • 6.3. Targeted Therapy
  • 6.4. Other Treatments

7. Global Leukemia Therapeutics Market, By Type of Leukemia, 2019-2030(USD Million)

  • 7.1. Acute Lymphocytic Leukemia
  • 7.2. Acute Myeloid Leukemia
  • 7.3. Chronic Lymphocytic Leukemia
  • 7.4. Chronic Myeloid Leukemia
  • 7.5. Other Type of Leukemias

8. Global Leukemia Therapeutics Market, By Molecule Type, 2019-2030 (USD Million)

  • 8.1. Small Molecules
  • 8.2. Biologics

9. Global Leukemia Therapeutics Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1 AbbVie Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2 Amgen Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3 Astellas Pharma Inc.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4 AstraZeneca PLC
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5 Bristol-Myers Squibb Company
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6 Eli Lilly and Company Ltd.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7 Gilead Sciences Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8 iCell Gene therapeutics
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9 Merck & Company Inc.
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10 Novartis AG
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11 Otsuka Holdings Company Ltd.
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12 Pfizer Inc.
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13 Roche Holding AG
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14 Sanofi
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15 Stemline Therapeutics Inc.
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16 Takeda Pharmaceutical Company Ltd.
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments